Colon Cancer

  • Cathy Eng
  • Patrick Lynch
  • John Skibber


Globally, colorectal cancer is one of the leading causes of cancer morbidity and mortality. In the USA, it is the third leading cause of cancer and the second leading cause of cancer death; colorectal cancer will be diagnosed in approximately 141,210 Americans this year and in 1 of every 20 Americans in their lifetime [1]. More than two-thirds of these cases will originate from the colon vs. the rectum. For the purpose of this chapter, we will focus on the more common colon cancer.


Colorectal Cancer Colon Cancer Familial Adenomatous Polyposis Mismatch Repair Protein Adequate Surgical Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer facts and figures, 2011. Atlanta: American Cancer Society; 2011.Google Scholar
  2. 2.
    Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 2008;143:1204–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.PubMedCrossRefGoogle Scholar
  4. 4.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Deng G, Peng E, Gum J, et al. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer. 2002;86:574–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94.PubMedGoogle Scholar
  8. 8.
    Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583–96.PubMedCrossRefGoogle Scholar
  9. 9.
    West NP, Hohenberger W, Weber K, et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol. 2010;28:272–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Joseph NE, Sigurdson ER, Hanlon AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10:213–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III Trial N0147 [abstract CRA3507]. J Clin Oncol. 2010;28(Suppl):959s.Google Scholar
  12. 12.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Gastroenterology, Hepatology, & NutritionThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations